Australia's most trusted
source of pharma news
Saturday, 27 July 2024
Posted 13 May 2024 AM
Sanofi has struck a $1.2 billion deal with Novavax to co-commericalise the struggling pharma's COVID-19 shot Nuvaxovid as well as develop novel flu-Covid combination vaccines.
The agreement announced late Friday has provided a desperately needed lifeline to Novavax - news that it would partner with one of the world's most experienced vaccine developers sent the company's share price surging by 130 per cent.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.